Key facts
- This page summarizes Brian Baranick's Form 4 filing for EXACT SCIENCES CORP (EXAS).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Aug 2024, 17:30.
Brian Baranick - 05 Aug 2024 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)
- Reporting relationship
- EVP, GM, Precision Oncology
- Issuer ticker
- EXAS
- Reported as of
- 05 Aug 2024
- Net transaction value
- -$76,684
- SEC form
- 4
- Accepted by SEC
- 06 Aug 2024, 17:30:04 UTC
- Prior SEC filing
- 02 May 2024
- Next SEC filing
- 19 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Baranick by Mark Busch, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian Baranick filed Form 4 for EXACT SCIENCES CORP (EXAS) on 06 Aug 2024.
Change
- Previous filing in this sequence was filed on 02 May 2024.
- Current net transaction value: -$76,684.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EXAS
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +2,712
- Change %
- +20%
- Price
- $0.000000
- Shares after
- 15,991
- Date
- 05 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
EXAS
transaction
Common Stock
Tax liability
- Transaction value
- $76,684
- Shares
- -1,375
- Change %
- -8.6%
- Price
- $55.77
- Shares after
- 14,616
- Date
- 05 Aug 2024
- Ownership
- Direct
- Footnotes
- F2, F3
EXAS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 454
- Date
- 05 Aug 2024
- Ownership
- Held in 401(k) Plan
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EXAS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -2,712
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 05 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,712
- Exercise price
- Footnotes
- F1, F4
EXAS
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +21,401
- Change %
- Price
- $0.000000
- Shares after
- 21,401
- Date
- 05 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,401
- Exercise price
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents a restricted stock unit award that fully vested on August 5, 2024.
Footnote F2
In addition to the shares of Common Stock reported on this Form 4, which total 15,070 shares, Mr. Baranick also holds, in the aggregate, an additional 65,007 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
Footnote F3
Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units on August 5, 2024.
Footnote F4
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F5
These restricted stock units vest in four equal annual installments beginning on August 5, 2025.